In a challenging year for ProPhase Labs, now valued at just $10 million in market cap, the company's stock has plummeted to a 52-week low, touching down at $0.41. This significant downturn reflects a ...
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare ...
StockNews.com assumed coverage on shares of ProPhase Labs (NASDAQ:PRPH – Free Report) in a report released on Thursday. The firm issued a sell rating on the stock. ProPhase Labs Stock Performance ...
Transaction Eliminates More Than $20 Million in Debt, and Other Financial Obligations, Provides $2 million in Cash and Significantly Enhances the Company’s Balance Sheet and Liquidity The ...
Mitosis is conventionally divided into five stages known as prophase, prometaphase, metaphase, anaphase, and telophase. While mitosis is taking place, there is no cell growth and all of the ...
ProPhase Labs shares are trading lower by 50% during Friday's session. The company announced a 4.17 million share offering at 72 cents per share, totaling $3 million.